AbbVie is one of America's most prominent biopharmaceutical companies, spun out of Abbott Laboratories in 2013 and built around a commercial drug portfolio of considerable scale and reach. Listed on the NYSE under the ticker ABBV, the company is perhaps best known as the maker of Humira, for many years the world's best-selling prescription medicine, though its strategic priority in recent years has been diversifying beyond Humira as biosimilar competition has eroded that franchise.
The diversification effort has been substantial. AbbVie's acquisitions of Allergan and a series of oncology and immunology assets have broadened the pipeline meaningfully, with Skyrizi and Rinvoq emerging as the next generation of growth drivers. For traders, AbbVie is an interesting combination of defensive pharmaceutical income: the company has a strong dividend track record and binary event risk around clinical trial outcomes and regulatory decisions that can move the share price sharply in either direction.
Please note this is marketing communication, not recommendation or advice.
hesabên mişterî
FxPro ji sala 1999 ve karûbarên bazirganiya serhêl pêşkêşî mişteriyên xwe dike û niha di 173 welatan de xizmet dike.
Xelat
FxPro di pîşesaziyê de her dem nasname wergirtiye û heya niha ji bo kalîteya karûbarên xwe zêdetirî 145 xelata navneteweyî wergirtiye.
xizmeta mişterî
Tîma me ya xizmeta mişterî ya pirzimanî ya fedakar 24/5 dixebite da ku alîkariya we ya bêhempa peyda bike.
rêzikên pîşesaziyê
FxPro di bin çavdêriya rêzikdarî ya hişk a gelek dadweriyê de dixebite, di nav de destûra ji aliyê FCA ve li Keyaniya Yekbûyî — yek ji rêzikdarên darayî yên herî pêbawer ên cîhanî.
